drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Patient-specific chimeric monoclonal antibodies generated from each subject’s tumor, targeting mutated cell-surface neoepitopes absent from normal tissue. Mechanism: binding to mutant extracellular epitopes to mediate Fc-dependent effector functions (ADCC, macrophage phagocytosis) and complement-dependent cytotoxicity (CDC), with potential blockade of oncogenic receptor signaling.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Chimeric
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Personalized chimeric monoclonal antibodies bind patient-specific mutated cell-surface neoepitopes on tumor cells, engaging Fcγ receptors to drive ADCC and macrophage phagocytosis and activating complement for CDC; may also block oncogenic receptor signaling when the target is a driver receptor.
drug_name
Moonshot antibodies
nct_id_drug_ref
NCT06674538